- Elevance Health Inc (NYSE:ELV), previously known as Anthem Inc, has reported Q2 FY22 adjusted EPS of $8.04, up 14.4% Y/Y, beating the consensus of $7.74.
- Operating revenue are up 15.6% to $38.5 billion, slightly beating the expectations of $38.13 billion, driven by higher premium revenue due to membership growth in Medicaid, MMM & Paramount Advantage acquisitions, and premium rate increases to cover overall cost trends.
- The benefit expense ratio was 87%, increasing 20 basis points versus the prior-year quarter.
- Operating cash flow was $2.5 billion, or 1.5x net income, increasing $769 million when compared year-over-year.
- Medical enrollment increased 6.1% Y/Y to 47.1 million members.
- The company announced a Q3 2022 dividend of $1.28 per share payable on September 23 with a record date of September 9.
- FY22 Outlook: Anthem expects FY22 adjusted EPS of more than $28.70 (consensus $28.64) versus prior guidance of $28.40.
- Price Action: ELV shares closed 3.46% higher at $497.43 on Tuesday.
Goldilocks 2024: Investors Increasingly Optimistic On Profits Outlook For Next Year
Equity allocation is on the rise as investors expect rally to continue, but some trades are becoming overcrowded, particularly Big Tech.
